Last Updated on September 3, 2025 by The Health Master
USFDA Inspection
That’s quite the breath of fresh air for Zydus Lifesciences! The Ahmedabad formulation manufacturing plant has officially completed the United States Food and Drug Administration inspection (USFDA inspection) with zero observations.
Such an observation score is practically unheard of.
This USFDA inspection is quite the reflection of success for Zydus, especially as the company readies new drug launches in the United States very shortly.
What Does This USFDA Inspection Mean?
Drug manufacturers are required to get formal approval from the USFDA to sell new products in the United States.
One of the final processes is a formal USFDA inspection of the manufacturer’s plant.
This Plant Pre-Approval Inspection was exactly what it sounds like: a thorough investigation of whether or not the plant could make a drug’s promise in the first place—properly, safely, and reliably.
From August 11 to August 13, 2025, the USFDA team evaluated every step of the process, from the machines to quality control of cGMP (current Good Manufacturing Practices) compliance.
For Zydus to be notified with zero observations, this means that each step, each person, and quality control efforts are on par and appropriately in line with regulatory expectations.
The Importance of Zero Observations
What’s the big deal about receiving zero observations?
In a way, it’s like report card results for the plants.
Even the best plants end up getting a few notes or suggestions from observing them for quality enhancement.
When none occur, it not only shows how incredibly rare this is but also that the USFDA has extreme confidence that all operations were clean and effective, that Zydus submitted data computed correctly, and that the end production will be safe drugs.
This is important for the pharmaceutical industry; trust is the basis by which new drugs are made, and 9 times out of 10, the efficacy of this drug relies on investor trust and physician/patient trust.
What Happens After?
Zydus is due to receive approval for three products that were under review during this USFDA inspection.
While specific products have not been delineated.
This is a fantastic sign for Zydus to solidify its reputation for American treatment.
Q: What is a USFDA inspection?
A: An audit created by the United States Food and Drug Administration (USFDA) to determine whether or not a drug manufacturer’s plant and services comply with quality and safety standards before being given approval to sell their products in America.
Q: What does “Zero observations” mean?
A: The auditors found no problems or issues during their time there. The plant passed with flying colors.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
USFDA inspection: At Torrent Pharma with zero observations at Vizag
USFDA inspection: At Granules India arm with 1 observation
USFDA inspection: At Senores Pharma arm with 3 observations
USFDA inspection: At Unichem with 3 observations: Roha
USFDA inspection: At Natco Pharma with 7 observations: Hyderabad
Key Notes on Revised Schedule M: Plant and equipment
Drug recall: Alembic recalls 9,492 bottles of Doxepin Capsules
Focus on R&D, secure Patents for New Drugs: PM
Big Push for Safer Medicines: Launches “SHRESTH” to rank States
Drug recall: Sun Pharma recalls 11,328 bottles of BP drug
New Draft Standards for IVD Medical Devices: CDSCO
UCPMP 2024: A New Era for Ethical Pharma Marketing
Final Call: No more extensions for WHO-GMP certification
CDSCO Approval: Panel Nod For Alfuzosin-Tadalafil FDC PMS Study
